Acadian Asset Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-814
| Closed | -$23K | – | 2148 |
|
|
2024
Q3 | $23K | Buy |
+814
| New | +$23K | ﹤0.01% | 1961 |
|
|
2024
Q1 | – | Sell |
-1,169
| Closed | -$25K | – | 1780 |
|
|
2023
Q4 | $25K | Sell |
1,169
-10,719
| -90% | -$229K | ﹤0.01% | 1570 |
|
|
2023
Q3 | $145K | Sell |
11,888
-43,767
| -79% | -$534K | ﹤0.01% | 1247 |
|
|
2023
Q2 | $625K | Hold |
55,655
| – | – | ﹤0.01% | 996 |
|
|
2023
Q1 | $402K | Hold |
55,655
| – | – | ﹤0.01% | 1108 |
|
|
2022
Q4 | $625K | Buy |
55,655
+36,913
| +197% | +$415K | ﹤0.01% | 979 |
|
|
2022
Q3 | $245K | Buy |
18,742
+2,207
| +13% | +$28.9K | ﹤0.01% | 1164 |
|
|
2022
Q2 | $208K | Buy |
16,535
+10,559
| +177% | +$133K | ﹤0.01% | 1190 |
|
|
2022
Q1 | $342K | Buy |
5,976
+743
| +14% | +$42.5K | ﹤0.01% | 1088 |
|
|
2021
Q4 | $620K | Buy |
+5,233
| New | +$620K | ﹤0.01% | 954 |
|
|
2019
Q2 | – | Sell |
-343
| Closed | -$69K | – | 2030 |
|
|
2019
Q1 | $69K | Buy |
+343
| New | +$69K | ﹤0.01% | 1607 |
|
|
2018
Q4 | – | Sell |
-2,169
| Closed | -$519K | – | 1827 |
|
|
2018
Q3 | $519K | Sell |
2,169
-755
| -26% | -$181K | ﹤0.01% | 870 |
|
|
2018
Q2 | $773K | Buy |
2,924
+1,690
| +137% | +$447K | ﹤0.01% | 796 |
|
|
2018
Q1 | $307K | Buy |
1,234
+831
| +206% | +$207K | ﹤0.01% | 967 |
|
|
2017
Q4 | $54K | Buy |
403
+221
| +121% | +$29.6K | ﹤0.01% | 1214 |
|
|
2017
Q3 | $22K | Buy |
+182
| New | +$22K | ﹤0.01% | 1214 |
|
|
2017
Q1 | – | Sell |
-19
| Closed | -$2K | – | 1767 |
|
|
2016
Q4 | $2K | Buy |
+19
| New | +$2K | ﹤0.01% | 1572 |
|